# To Investigate Efficacy, Pharmacodynamics, and Safety of BC 007 in Participants With Long COVID

> **NCT05911009** · PHASE2 · COMPLETED · sponsor: **Berlin Cures GmbH** · enrollment: 119 (actual)

## Conditions studied

- Long Covid

## Interventions

- **DRUG:** BC 007 or matching placebo

## Key facts

- **NCT ID:** NCT05911009
- **Lead sponsor:** Berlin Cures GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-06-16
- **Primary completion:** 2024-06-26
- **Final completion:** 2024-09-04
- **Target enrollment:** 119 (ACTUAL)
- **Last updated:** 2024-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05911009

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05911009, "To Investigate Efficacy, Pharmacodynamics, and Safety of BC 007 in Participants With Long COVID". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05911009. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*